Clinical data | |
---|---|
Trade names | Frisium, Urbanol, Onfi, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612008 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Benzodiazepine |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 87% (oral) |
Protein binding | 80–90% |
Metabolism | Liver |
Metabolites |
|
Onset of action | 0.5–4 hours |
Elimination half-life |
|
Excretion | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.040.810 |
Chemical and physical data | |
Formula | C16H13ClN2O2 |
Molar mass | 300.74 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Clobazam, sold under the brand names Frisium, Onfi and others, is a benzodiazepine class medication that was patented in 1968.[3] Clobazam was first synthesized in 1966 and first published in 1969. Clobazam was originally marketed as an anxioselective anxiolytic since 1970,[4][5] and an anticonvulsant since 1984.[6] The primary drug-development goal was to provide greater anxiolytic, anti-obsessive efficacy with fewer benzodiazepine-related side effects.[4]